ESMO News: Three Generations of Cancer Immunotherapies
- This topic has 1 reply, 2 voices, and was last updated 8 years ago by
.
-
Posts
-
Despite this success, the field of onco-immunology is still young and much potential for growth and substantive translational and clinical improvements exist. The emerging therapies can be categorized into three generations.
1. Generation 1 encompasses the initiating agents in onco-immunology era, ipilimumab and sipuleucel-T,
2. At the centre of generation 2 of onco-immunology agents are PD-1 and PD-L1 blocking antibodies.
3. the variety of modalities under investigation include cytokines, cell therapies (including genetically engineered cells), checkpoint modulatory antibodies, cancer vaccines, BITEs that direct T cells to cancer cells (connectors)
The substantial improvements in survival observed with checkpoint-modulating immunotherapies are starting to change standards of care in oncology.
To read more, please use this link: http://www.esmo.org/Oncology-News/Three-Generations-of-Cancer-Immunotherapies
Marion
- The forum ‘New Developments’ is closed to new topics and replies.